Trials & Filings

Synta Posts Interim Monotherapy Trial Results

Shows clinical activity in breast cancer

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Synta Pharmaceuticals has posted interim results from the ENCHANT-1 trial, a single-arm multi-center Phase II proof-of-concept study designed to evaluate ganetespib, the company’s lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The results were presented during a poster session at the 2013 San Antonio Breast Cancer Symposium in San Antonio, TX. The trial is designed to evaluate the efficacy and safety of ganetespib monotherapy for treatment of HER...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters